MYK-461 is an investigational drug.
There have been 16 clinical trials for MYK-461.
The most recent clinical trial was a Phase 3 trial, which was initiated on May 29th 2018.
The most common disease conditions in clinical trials are Cardiomyopathies, Hypertrophy, and Cardiomyopathy, Hypertrophic. The leading clinical trial sponsors are MyoKardia, Inc., Bristol-Myers Squibb, and LianBio LLC.
There are two US patents protecting this investigational drug and fifty-one international patents.